34
Participants
Start Date
April 26, 2020
Primary Completion Date
May 15, 2021
Study Completion Date
March 9, 2023
AK104
Subjects will receive AK104 by intravenous administration
Sun Yat-sen University Cancer Center, Guangzhou
Lead Sponsor
Collaborators (1)
Akeso Pharmaceuticals, Inc.
OTHER
Akeso
INDUSTRY